Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 18-Sep-13 6:17 PM View:  | Hummel Albert F Director | Watson Pharmaceuticals Inc. (ACT) | 16-Sep-17 | Gift | 3,800 | -- | -- | (4%) 92.78K to 88.98K | |
| 02-Oct-13 9:16 PM View: | Stewart Robert A Pres-Global Operations | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 71,252 | -- | -- | (100%) 71.25K to 0 | |
| 02-Oct-13 9:21 PM View: | Klema Cathy Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 19,608 | -- | -- | (100%) 19.61K to 0 | |
| 02-Oct-13 9:14 PM View: | Paonessa Albert III President of Anda, Inc. | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 33,729 | -- | -- | (100%) 33.73K to 0 | |
| 02-Oct-13 9:19 PM View: | Fedida Michael J Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 25,382 | -- | -- | (100%) 25.38K to 0 | |
| 02-Oct-13 9:20 PM View: | Feldman Michel J Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 500 | -- | -- | (100%) 0.5K to 0 | |
| 02-Oct-13 9:03 PM View: | Fridriksdottir Hafrun Sr VP, Global Generics R&D | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 5,645 | -- | -- | (100%) 5.64K to 0 | |
| 02-Oct-13 8:44 PM View: | Bisaro Paul President & CEO Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 440,916 | -- | -- | (100%) 440.92K to 0 | |
| 02-Oct-13 9:10 PM View: | Joyce R Todd CFO-Global | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 73,812 | -- | -- | (96%) 77.09K to 3.28K | |
| 02-Oct-13 8:59 PM View: | Ebert Charles D Sr. VP, Research & Development | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 18,488 | -- | -- | (100%) 18.49K to 0 | |
| 02-Oct-13 9:18 PM View: | Bodine Chris W Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 14,629 | -- | -- | (100%) 14.63K to 0 | |
| 02-Oct-13 9:20 PM View: | Hummel Albert F Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 82,776 | -- | -- | (100%) 82.78K to 0 | |
| 02-Oct-13 9:23 PM View: | Taylor Ronald R Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 27,942 | -- | -- | (100%) 27.94K to 0 | |
| 02-Oct-13 9:26 PM View: | Weiss Fred G Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 27,275 | -- | -- | (100%) 27.27K to 0 | |
| 02-Oct-13 9:10 PM View: | Joyce R Todd CFO-Global | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 3,283 | -- | -- | (100%) 3.28K to 0 | |
| 02-Oct-13 8:49 PM View: | Buchen David A Chief Legal Officer-Global&Sec | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 89,966 | -- | -- | (100%) 89.97K to 0 | |
| 02-Oct-13 9:17 PM View: | Wilkinson George Fred Pres-Global Brands&Biosimilars | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 45,412 | -- | -- | (100%) 45.41K to 0 | |
| 02-Oct-13 9:20 PM View: | Feldman Michel J Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 12,941 | -- | -- | (96%) 13.44K to 0.5K | |
| 02-Oct-13 9:25 PM View: | Turner Andrew L Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 5,441 | -- | -- | (100%) 5.44K to 0 | |
| 02-Oct-13 8:53 PM View: | Eagan Patrick Chief HR Officer - Global | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 14,209 | -- | -- | (100%) 14.21K to 0 | |
| 02-Oct-13 9:11 PM View: | Mayr Charles M Chief Communic Off-Global | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 21,396 | -- | -- | (100%) 21.4K to 0 | |
| 02-Oct-13 9:23 PM View: | Michelson Jack Director | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 1,877 | -- | -- | (100%) 1.88K to 0 | |
| 02-Oct-13 9:13 PM View: | Olafsson Sigurdur O Pres.-Global Generics | Watson Pharmaceuticals Inc. (ACT) | 01-Oct-13 | Disposition | 96,947 | -- | -- | (100%) 96.95K to 0 | |
| 02-Oct-13 9:16 PM View: | Stewart Robert A Pres-Global Operations | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 121,951 | $144.00 | $17,560,900.00 | (63%) 193.2K to 71.25K | 83% |
| 02-Oct-13 9:14 PM View: | Paonessa Albert III President of Anda, Inc. | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 16,843 | $144.00 | $2,425,390.00 | (33%) 50.57K to 33.73K | 83% |
| 02-Oct-13 8:59 PM View: | Ebert Charles D Sr. VP, Research & Development | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 13,694 | $144.00 | $1,971,940.00 | (43%) 32.18K to 18.49K | 83% |
| 02-Oct-13 8:53 PM View: | Eagan Patrick Chief HR Officer - Global | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 15,291 | $144.00 | $2,201,900.00 | (52%) 29.5K to 14.21K | 83% |
| 02-Oct-13 8:49 PM View: | Buchen David A Chief Legal Officer-Global&Sec | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 38,441 | -- | -- | 39% 97.37K to 135.81K | |
| 02-Oct-13 9:13 PM View: | Olafsson Sigurdur O Pres.-Global Generics | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 181,845 | $144.00 | $26,185,700.00 | (65%) 278.79K to 96.95K | 83% |
| 02-Oct-13 8:49 PM View: | Buchen David A Chief Legal Officer-Global&Sec | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 45,848 | $144.00 | $6,602,110.00 | (34%) 135.81K to 89.97K | 83% |
| 02-Oct-13 9:16 PM View: | Stewart Robert A Pres-Global Operations | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Option Exercise | 75,000 | $86.86 | $6,514,500.00 | 63% 118.2K to 193.2K | |
| 02-Oct-13 9:17 PM View: | Wilkinson George Fred Pres-Global Brands&Biosimilars | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 39,612 | -- | -- | 80% 49.23K to 88.84K | |
| 02-Oct-13 9:03 PM View: | Fridriksdottir Hafrun Sr VP, Global Generics R&D | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 5,510 | $144.00 | $793,440.00 | (49%) 11.15K to 5.64K | 83% |
| 02-Oct-13 8:53 PM View: | Eagan Patrick Chief HR Officer - Global | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 11,952 | -- | -- | 81% 14.7K to 26.65K | |
| 02-Oct-13 9:11 PM View: | Mayr Charles M Chief Communic Off-Global | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 20,379 | -- | -- | 91% 22.48K to 42.86K | |
| 02-Oct-13 8:53 PM View: | Eagan Patrick Chief HR Officer - Global | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Option Exercise | 2,851 | -- | -- | 11% 26.65K to 29.5K | |
| 02-Oct-13 9:13 PM View: | Olafsson Sigurdur O Pres.-Global Generics | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 44,149 | -- | -- | 52% 84.64K to 128.79K | |
| 02-Oct-13 9:16 PM View: | Stewart Robert A Pres-Global Operations | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 44,312 | -- | -- | 60% 73.89K to 118.2K | |
| 02-Oct-13 9:13 PM View: | Olafsson Sigurdur O Pres.-Global Generics | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Option Exercise | 150,000 | $86.86 | $13,029,000.00 | 116% 128.79K to 278.79K | |
| 02-Oct-13 8:44 PM View: | Bisaro Paul President & CEO Director | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 162,076 | $144.00 | $23,338,900.00 | (27%) 602.99K to 440.92K | 83% |
| 02-Oct-13 9:14 PM View: | Paonessa Albert III President of Anda, Inc. | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 16,760 | -- | -- | 50% 33.81K to 50.57K | |
| 02-Oct-13 9:17 PM View: | Wilkinson George Fred Pres-Global Brands&Biosimilars | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 43,429 | $144.00 | $6,253,780.00 | (49%) 88.84K to 45.41K | 83% |
| 02-Oct-13 9:03 PM View: | Fridriksdottir Hafrun Sr VP, Global Generics R&D | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 4,318 | -- | -- | 250% 1.73K to 6.04K | |
| 02-Oct-13 9:03 PM View: | Fridriksdottir Hafrun Sr VP, Global Generics R&D | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Option Exercise | 5,110 | -- | -- | 85% 6.04K to 11.15K | |
| 02-Oct-13 8:44 PM View: | Bisaro Paul President & CEO Director | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 140,760 | -- | -- | 30% 462.23K to 602.99K | |
| 02-Oct-13 9:10 PM View: | Joyce R Todd CFO-Global | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 38,443 | -- | -- | 46% 83.75K to 122.2K | |
| 02-Oct-13 9:11 PM View: | Mayr Charles M Chief Communic Off-Global | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 21,462 | $144.00 | $3,090,530.00 | (50%) 42.86K to 21.4K | 83% |
| 02-Oct-13 9:10 PM View: | Joyce R Todd CFO-Global | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Payment of Exercise | 45,101 | $144.00 | $6,494,540.00 | (37%) 122.2K to 77.09K | 83% |
| 02-Oct-13 8:59 PM View: | Ebert Charles D Sr. VP, Research & Development | Watson Pharmaceuticals Inc. (ACT) | 30-Sep-13 | Grant | 12,212 | -- | -- | 61% 19.97K to 32.18K | |
| 24-Sep-13 6:01 PM View: | Wilkinson George Fred Pres-Global Brands&Biosimilars | Watson Pharmaceuticals Inc. (ACT) | 21-Sep-13 | Payment of Exercise | 3,240 | $135.50 | $439,020.00 | (6%) 52.47K to 49.23K | 82% |
